AU2001278913A1 - Method for preventing and/or decreasing amyloid production with polycyclic compounds - Google Patents
Method for preventing and/or decreasing amyloid production with polycyclic compoundsInfo
- Publication number
- AU2001278913A1 AU2001278913A1 AU2001278913A AU7891301A AU2001278913A1 AU 2001278913 A1 AU2001278913 A1 AU 2001278913A1 AU 2001278913 A AU2001278913 A AU 2001278913A AU 7891301 A AU7891301 A AU 7891301A AU 2001278913 A1 AU2001278913 A1 AU 2001278913A1
- Authority
- AU
- Australia
- Prior art keywords
- preventing
- polycyclic compounds
- amyloid production
- decreasing amyloid
- decreasing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/617,147 | 2000-07-17 | ||
| US09/617,147 US6472436B1 (en) | 2000-07-17 | 2000-07-17 | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
| PCT/US2001/022122 WO2002005813A2 (en) | 2000-07-17 | 2001-07-13 | Method for preventing and/or decreasing amyloid production with polycyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001278913A1 true AU2001278913A1 (en) | 2002-01-30 |
Family
ID=24472451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001278913A Abandoned AU2001278913A1 (en) | 2000-07-17 | 2001-07-13 | Method for preventing and/or decreasing amyloid production with polycyclic compounds |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US6472436B1 (en) |
| AU (1) | AU2001278913A1 (en) |
| WO (1) | WO2002005813A2 (en) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7479482B2 (en) * | 2001-11-21 | 2009-01-20 | New York University | Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto |
| CA2473102A1 (en) * | 2002-01-29 | 2003-07-29 | Protemix Corporation Limited | Suppression of cytotoxic protein conformers |
| US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
| WO2005000193A2 (en) * | 2003-06-30 | 2005-01-06 | Tel Aviv University Future Technology Development L.P. | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
| PT1511710E (en) * | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer s disease, type 2 diabetes, and parkinson s disease |
| AU2003261834A1 (en) * | 2002-08-30 | 2004-05-04 | Bf Research Institute, Inc. | Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein |
| US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
| EP1583713B1 (en) * | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
| CA2540407A1 (en) * | 2003-09-25 | 2005-03-31 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
| WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
| EP1781310B1 (en) | 2004-08-02 | 2015-10-14 | Ramot at Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
| US7786086B2 (en) * | 2004-09-08 | 2010-08-31 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
| US10004828B2 (en) * | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
| US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
| WO2008005577A2 (en) * | 2006-07-07 | 2008-01-10 | University Of South Florida | Compositions of polyphenols and methods of use |
| US8778986B1 (en) * | 2007-01-25 | 2014-07-15 | University Of South Florida | Treatment of glycogen synthase kinase-based disease |
| RU2009134137A (en) * | 2007-02-14 | 2011-03-27 | Марс, Инкорпорейтед (Us) | NEUROGENIC COMPOUNDS |
| WO2008109517A1 (en) * | 2007-03-02 | 2008-09-12 | University Of South Florida | Neurodegenerative disease treatment using jak/stat inhibition |
| GB0718718D0 (en) | 2007-09-25 | 2007-11-07 | Pentraxin Therapeutics Ltd | Compound and use thereof |
| EP2307342B1 (en) | 2008-07-02 | 2017-06-21 | British Columbia Cancer Agency Branch | Diglycidic ether derivative therapeutics and methods for their use |
| JP5940982B2 (en) * | 2010-01-06 | 2016-06-29 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | Bisphenol derivatives and their use as androgen receptor activity modulators |
| US20150065449A1 (en) | 2011-08-12 | 2015-03-05 | Florida State University Research Foundation, Inc. | Treating Amyloidoses With A Vitamin B12 Composition Including Melatonin, Resveratrol, and EGCG |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| BR112015028174A2 (en) | 2013-05-10 | 2017-07-25 | British Columbia Cancer Agency Branch | compound, pharmaceutical composition, use of a pharmaceutical composition, and methods for modulating androgen receptor activity and for increasing the bioavailability of an androgen receptor modulator |
| KR20160054523A (en) | 2013-09-09 | 2016-05-16 | 브리티쉬 콜롬비아 캔써 에이전시 브랜치 | Halogenated compounds for cancer imaging and treatment and methods for their use |
| DK3988541T3 (en) | 2015-01-13 | 2024-09-16 | British Columbia Cancer Agency Branch | HETEROCYCLIC COMPOUNDS FOR IMAGING AND TREATMENT OF CANCER AND METHODS OF USING THESE |
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| WO2017096049A1 (en) | 2015-12-03 | 2017-06-08 | The University Of North Carolina At Pembroke | Materials for cathepsin b enhancement and methods of use |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| PE20211543A1 (en) | 2018-10-18 | 2021-08-16 | Essa Pharma Inc | ANDROGEN RECEIVER MODULATORS AND METHODS FOR THEIR USE |
| US12109179B2 (en) | 2019-03-28 | 2024-10-08 | Essa Pharma Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| US20210323931A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3408407A (en) * | 1964-03-27 | 1968-10-29 | Union Carbide Corp | Novel bisphenols of cyclohexadiene |
| KR900012875A (en) * | 1989-02-08 | 1990-09-03 | 오스카 아끼히꼬 | A biphenyl derivative, a neuronal cell-denatured restoration or protection agent, and a method for producing a cuneyl derivative used therein |
| EP0688327B1 (en) * | 1993-03-01 | 1999-05-06 | Glycan Pharmaceuticals, Inc. | Analogs for specific oligosaccharide-protein interactions and uses therefor |
| CA2214247C (en) | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| JPH08268949A (en) * | 1995-03-29 | 1996-10-15 | Eisai Co Ltd | Diphenylmethylene derivative |
| US5783434A (en) * | 1995-06-06 | 1998-07-21 | Tung; Jay S. | Cathepsin and methods and compositions for inhibition thereof |
| JPH11510144A (en) * | 1995-07-24 | 1999-09-07 | ユニバーシティー・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド | Use of non-estrogenic polycyclic phenolic compounds for the manufacture of a medicament for imparting neuroprotection to cells |
| US5985242A (en) | 1995-10-27 | 1999-11-16 | Praecis Pharmaceuticals, Inc. | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
| FR2753969B1 (en) * | 1996-09-27 | 1998-10-30 | Adir | NOVEL FLAVON DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| AU5474198A (en) * | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| JP2002501018A (en) * | 1998-01-26 | 2002-01-15 | マイトコー | Mitochondrial protective agents for treating mitochondrial-related diseases |
| FR2778337B1 (en) * | 1998-05-05 | 2001-08-31 | Inst Nat Sante Rech Med | ARYLHYDROCARBON RECEPTOR LIGAND ANTAGONISTS |
| AU5531599A (en) * | 1998-09-01 | 2000-03-21 | Lg Chemical Ltd. | Novel cdk inhibitors having flavone structure |
| CN1326450A (en) * | 1998-09-24 | 2001-12-12 | 三菱化学株式会社 | Hydroxyflavone Derivatives as Tau Kinase 1 Inhibitors |
-
2000
- 2000-07-17 US US09/617,147 patent/US6472436B1/en not_active Expired - Fee Related
-
2001
- 2001-07-13 WO PCT/US2001/022122 patent/WO2002005813A2/en not_active Ceased
- 2001-07-13 AU AU2001278913A patent/AU2001278913A1/en not_active Abandoned
-
2002
- 2002-10-11 US US10/269,477 patent/US7053116B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6472436B1 (en) | 2002-10-29 |
| WO2002005813A3 (en) | 2003-07-10 |
| WO2002005813A2 (en) | 2002-01-24 |
| US7053116B2 (en) | 2006-05-30 |
| US20030096859A1 (en) | 2003-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001278913A1 (en) | Method for preventing and/or decreasing amyloid production with polycyclic compounds | |
| AU2002212112A1 (en) | Profile composite component and method for the production thereof | |
| AU2001266072A1 (en) | Flat gasket and method for the production thereof | |
| AU2001256755A1 (en) | Biosensor and method for manufacturing the same | |
| AU2001266583A1 (en) | Epothilone derivatives and methods for making and using the same | |
| AU2002338336A1 (en) | Epothilone derivatives and methods for making and using the same | |
| AU2002250858A1 (en) | Capsule-in-capsule system and method for the production thereof | |
| AU4455601A (en) | Hole structure and production method for hole structure | |
| AU2001293753A1 (en) | Method for the production of macrocyclic esters | |
| AU2001280270A1 (en) | Method of manufacturing structural members and the members provided by such method | |
| AU5057600A (en) | Component and method for the production thereof | |
| AU2003297177A1 (en) | Spliced yarn and method for forming the same | |
| AU2002241739A1 (en) | Antimycobacterial compounds and method for making the same | |
| AU4284500A (en) | Multilayer membranes and method for the production thereof | |
| AU2001291288A1 (en) | Webpad and method for using the same | |
| AU2000267048A1 (en) | Bases for cutout circuits and method for the production thereof | |
| AU4751300A (en) | Method and device for the continuous production of NaAlCl4 or NaFeCl4 | |
| AU2001289844A1 (en) | Amifostine-monohydrate and a method for the production thereof | |
| AU2002221190A1 (en) | Paper quilt and method for manufacturing the same | |
| AU2001274004A1 (en) | Method for the production of 2- coumarone and substituted 2-coumarones | |
| AU4645401A (en) | Flat composite component and method for the production thereof | |
| IL152795A0 (en) | Method for the production of 2-coumarone and substituted 2-coumarones | |
| AU4235201A (en) | Indentor and method for producing the same | |
| AU2001260184A1 (en) | Connection device and method for the production thereof | |
| AU2001292825A1 (en) | Webpad and method for using the same |